Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy

To meet the needs of patients, Canadian surgical and medical oncology leaders in the treatment of peritoneal surface malignancies (psms), together with patient representatives, formed the Canadian HIPEC Collaborative Group (chicg). The group is dedicated to standardizing and improving the treatment of psm in Canada so that access to treatment and, ultimately, the prognosis of Canadian patients with psm are improved.Patients with resectable psm arising from colorectal or appendiceal neoplasms should be reviewed by a multidisciplinary team including surgeons and medical oncologists with experience in treating patients with psm. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be offered to appropriately selected patients and performed at experienced centres.The aim of this publication is to present guidelines that we recommend be applied across the country for the treatment of psm.

show abstract

“…After resection, the completeness of cytoreduction (cc) 27,29,55 is evaluated using the cc score (Table v).…”

Section: Surgical Considerationsmentioning

confidence: 99%

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In contrast, rectal cancer patients having the same treatments had a median survival of 17 months and there were no longterm survivors [10]. Verwaal showed that the prognosis of rectal cancer patients treated for peritoneal metastases was markedly reduced (p = 0.069) [7]. A similar phenomenon was reported by Yang et al in the prospective randomized trial of gastric cancer patients treated with CRS and HIPEC for peritoneal metastases.…”

Section: Prior Surgical Score (Pss)mentioning

confidence: 55%

“…Verwaal and colleagues reported 15 patients with signet ring cells had a median survival of 13.0 months as compared to 86 patients without signet ring cells identified in peritoneal metastases had a survival of 21.4 months (p = 0.008). These authors recommended that signet ring cells in peritoneal metastases are a relative contraindication to the use of CRS and HIPEC to treat peritoneal metastases in colon cancer patients [7]. Also, it is well established that signet ring cells carry a poor prognosis in patients with gastric cancer.…”

Section: Histopathology Including Lymph Node Statusmentioning

confidence: 99%

Preoperative Assessment of Cancer Patients with Peritoneal Metastases for Complete Cytoreduction

Sugarbaker

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…There were no five-year survivors in the rectal cancer group as compared to 30 in the colon cancer group [16]. Verwaal showed in a multivariate analysis of 102 patients that peritoneal metastases treated with CRS and HIPEC had a poorer prognosis (p=0.069) [17].…”

Section: Modification Of Primary Rectal Cancer Surgery In Patients Wimentioning

confidence: 96%

Management Of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC

Sugarbaker¹,

Gléhen²

2017

Cancer Surg

View full text Add to dashboard Cite

Background: Peritoneal metastases (PM) will be unexpectedly present in approximately 10% of colorectal cancer patients having primary cancer resection. In the past this was considered to be an incurable condition with a terminal outcome. In patients determined to have peritoneal dissemination at the time of resection, the intervention was considered palliative. Recently, long term benefit from definitive treatment of PM with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become a reality. These treatments are now appropriate for primary appendiceal and colorectal cancer determined to have PM at the time of resection.

show abstract

Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy

Abstract: The survival of patients with peritoneal carcinomatosis of colorectal origin is dominated by the extent of disease and the amount of residual tumour after cytoreduction.

Cited by 196 publications

References 23 publications

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms

Preoperative Assessment of Cancer Patients with Peritoneal Metastases for Complete Cytoreduction

Management Of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC

Contact Info

Product

Resources

About